Paris-based Metyos has raised €2.3mn in pre-seed funding to improve the lives and health outcomes of chronic kidney disease patients with its biowearable technology.
Chronic kidney disease (CKD) affects 10% of the population and is the third fastest-growing cause of death worldwide. It’s also associated with a heavy financial impact on healthcare, with its treatment costing the EU €140bn per year.
To fight the disease, Metyos has developed a biowearable sensor in the form of a patch, which provides real-time readings on biomarkers related to CKD.
The readings are fed into the startup’s disease management platform, which doctors can use to monitor a patient’s kidney function. This includes tracking the impact of medication and diet and observing warning signs of symptoms such as renal failure or hyperkalemia (the abnormal increase of potassium levels).
The
Source : The Next Web